Weight loss predicts poor prognosis in patients treated with concurrent chemoradiotherapy for stage III non-small cell lung cancer

作者：Wei, Min; Xie, Conghua^*

来源：Biomedical Research-India, 2017, 28(14): 6308-6313.

• Concurrent chemoradiotherapy
• Non-small cell lung cancer
• Weight loss

The aims of this study were to investigate the impact of weight loss experienced during initial Concurrent Chemoradiotherapy (C-CRT) on survival outcome of patients with stage III Non-Small Cell Lung Cancer (NSCLC). We retrospectively reviewed 98 patients with stage III NSCLC who received C-CRT from January 2007 to December 2010. Patients were treated with systemic chemotherapy regimen of Cisplatin/Docetaxel and concurrent thoracic radiotherapy at a median dose of 66 Gy (range 60 to 70 Gy). Weight loss was defined as weight loss of more than 5% during C-CRT. In 60% of the patients weight loss was observed. In our retrospective clinical study, Kaplan-Meier curves show that patients with weight loss have poorer Progression-Free Survival (PFS) and Overall Survival (OS) (P=0.005, 0.001). Multivariate Cox regression analysis indicated that weight loss could influence the overall survival time of patients in stage III NSCLC, with the hazard ratio of 1.869 (95% CI, 1.175-2.975; P=0.008). Weight loss may be a useful prognostic factor to predict treatment outcome in stage III NSCLC treated with C-CRT.

• 出版日期2017
• 单位武汉大学; 中山大学